Who is sponsoring NCT05629923?

NCT05629923 is sponsored by University of Rome Tor Vergata.

What drugs are being tested in NCT05629923?

Interventions in NCT05629923: tixagevimab-cilgavimab(AZD7442, AstraZeneca).

What condition does NCT05629923 study?

NCT05629923 studies COVID-19 Pandemic, Transplant-Related Disorder.

Is NCT05629923 still recruiting?

NCT05629923 is currently completed. Last updated 20 December 2022.

Last reviewed 2022-12-20 · How we verify

NCT05629923

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS

Completed Last updated 20 December 2022

What this trial tests

trial testing tixagevimab-cilgavimab(AZD7442, AstraZeneca) in COVID-19 Pandemic in 306 participants. Completed in 30 November 2022.

Timeline

1 February 2022

Primary endpoint
1 November 2022

30 November 2022

Quick facts

Lead sponsor	University of Rome Tor Vergata
Status	Completed
Study type	OBSERVATIONAL
Enrollment	306
Start date	1 February 2022
Primary completion	1 November 2022
Estimated completion	30 November 2022
Sites	1 location across Italy

Drugs / interventions tested

tixagevimab-cilgavimab(AZD7442, AstraZeneca) — full drug profile →

Conditions studied

COVID-19 Pandemic — all drugs for COVID-19 Pandemic →
Transplant-Related Disorder — all drugs for Transplant-Related Disorder →

Sponsor

University of Rome Tor Vergata

Who can join

Adults 18 to 99, any sex, with COVID-19 Pandemic or Transplant-Related Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to evaluate the immune response after COVID-19 vaccination in Liver(LT) and Kidney(KT) transplant recipient. The main question it aims to answer are: * the evaluation of the antibody response after complete vaccination * the efficacy of prophylaxis with long-acting-antibody prophylaxis (LAAB) All LT and KT patients during follow-up have been enrolled. anti-COVID-19 title was obtained by Electrochemiluminescence Immunoassay (ECLIA) Test(Elyx, Roche). In the case of antibody level \<100 IU/ml, patients were invited to prophylaxis with tixagevimab-cilgavimab(AZD7442, AstraZeneca). At three months, a follow-up was performed to assess any COVID-19 infection. At Six months another anti-COVID-19 title is obtained by ECLIA Test(Elyx, Roche) in LT and KT who undergo to LAAB.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients.
Angelico R, Romano F, Coppola L, Materazzo M, et al · · 2023 · cited 4× · PMID 38138204 · DOI 10.3390/medicina59122101

Verify or expand the search:

Other recruiting trials for COVID-19 Pandemic

Currently open trials in the same condition.

NCT05825651 — Long COVID and Its Associations With Health Outcomes in Older Adults · active not recruiting
NCT06927622 — Corona Virus Disease 2019 Cohort Study · recruiting
NCT05096260 — Getting to Yes, Michigan! (G2YMI) · NA · active not recruiting
NCT06208943 — Neural and Cognitive Consequences of COVID-19 Survival · recruiting

Other University of Rome Tor Vergata trials

Trials by the same sponsor.

NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT07313358 — 10119473 -VIROMARKERS HDV Biomarkers Study · not yet recruiting
NCT07286461 — VIROMARKERS GA n.101194735 - CMV and TTV Biomarkers Study Protocol · not yet recruiting
NCT07067749 — Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer · Phase 3 · recruiting
NCT06711744 — ISQ Differences Between Different Implants in Post-extraction Sockets · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05629923 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rome Tor Vergata
Last refreshed: 20 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05629923.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing